Dr Lal Pathlabs

Q4 FY26Healthcare Services

Dr Lal Pathlabs Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,894

Market cap₹31.8K Cr

P/E56.6

Updated23 Aug 2026

Read5 min read

The short version

Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery. - EBITDA margin is expected to be steady at around 27%-28% in FY27, with investments in infrastructure and organic growth balancing margin expansion. - Net profit margin (PAT margin) also expected to remain around 18%-19%, supported by margin stability despite ongoing investments. - EPS for FY26 was Rs.

From Dr Lal Pathlabs's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually).
Patient volume growth is expected to improve gradually, supported by expansion of labs and collection networks.
Recent quarter showed an 8.2% volume growth, but annualized growth (~5.3%) is a better indicator.
Growth is broad-based across regions, with sustained double-digit growth in Delhi NCR and improving growth in Suburban business.
Expansion in Tier 3 and Tier 4 geographies contributing positively without diluting realizations.
Increased focus on health packages and specialized testing, including the preventive healthcare brand Swasthfit (27% revenue contribution).
New labs and network additions (12-15 labs planned next year) will support volume growth.

2 more points management made on revenue & sales performance

Profitability & Margins

The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery.
EBITDA margin is expected to be steady at around 27%-28% in FY27, with investments in infrastructure and organic growth balancing margin expansion.
Net profit margin (PAT margin) also expected to remain around 18%-19%, supported by margin stability despite ongoing investments.
EPS for FY26 was Rs. 30.2 with growth over previous year Rs. 29.2; similar or modest growth expected as revenues grow.

2 more points management made on profitability & margins

See what Dr Lal Pathlabs said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

FY27 capex guidance is Rs. 100 crore - Rs. 120 crore.
Capex includes both maintenance and growth investments.
Growth capex planned for opening 12 to 15 new labs next year (14 labs added in current year).
Investments in a precision diagnostic lab with high-end complex testing equipment.
Incorporation of a subsidiary in Dubai as part of international expansion, considering both organic and inorganic opportunities including potential M&A in Middle East.
Some investments planned in radiology centers – slow and calibrated growth approach on radiology expansion, including integrated high-end radiology centers in Delhi NCR and possibly Tier 2 towns.

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹1.8K Cr

Rev 2Mar 2

5₹649 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The company maintains a strong balance sheet with net cash and cash equivalents of Rs. 1,526 crore, providing ample liquidity for future growth and expansion.
The management discussed allocation of capex for FY27 and FY28 (Rs. 100-120 crore) mainly towards lab expansions, infrastructure, and acquisitions but did not indicate a need for external fundraising.

- International expansion plans, including incorporation of a subsidiary in Dubai, will be funded through existing cash reserves. - Management remains open to inorganic growth opportunities (M&A) but no specific mention of financing through new debt or equity fundraising. In summary, Dr. Lal PathLabs currently relies on internal accruals and cash reserves for growth without disclosing any immediate plans for new debt or equity fundraising.

2 more points management made on fundraising & capital structure

See what Dr Lal Pathlabs said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided from the Q4 & FY26 Earnings Conference Call of Dr. Lal PathLabs Limited does not explicitly mention current or expected orderbook or pending orders. The discussion primarily focuses on operational performance, acquisitions, margin profiles, expansion plans, patient volume growth, capex guidance, and margin outlook. - No specific data or commentary on orderbook or pending orders is disclosed. - Focus is on network expansion (labs and collection centers), including franchising in Suburban areas. - Acquisition of Shahbazkers Diagnostic Centre to strengthen presence in Mumbai is mentioned. - Capex for FY27 is guided at Rs. 100-120 crore, supporting organic and inorganic growth.

2 more points management made on order book & pipeline

Dr Lal Pathlabs — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹703 Cr, net profit ₹132 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Dr Lal Pathlabs Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Gaudium IVF (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Apollo Hospitals Enterprise Ltd (Q4 FY26)
30% growth currently driven by top 5 markets; expansion planned into new markets. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY26 earnings…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Dr Lal Pathlabs Q4 FY26 results?

What is Dr Lal Pathlabs share price analysis?

Dr Lal Pathlabs currently shows a neutral. The stock trades at a P/E of 56.5 with a market cap of ₹31,794 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs planning capital expenditure?

FY27 capex guidance is Rs.

Keep Dr Lal Pathlabs on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.